Consumer Update
Health Care: Drugs
Isis Pharmaceuticals (ISIS: NASDAQ)
$8.66 -0.09 | -1.03%
02/08/12 - 02:39 PM ET
364.21K / 644.20K
Vol / Avg. Vol:8.75 / 8.75
Open / Prev. Close:8.34 - 8.80
Today's Range:6.25 - 9.61
52 Wk Range:21.36%
Performance YTD:TheStreet Rating:
Portfolios with ISIS
- Portfolio NameUser Type
- UserCy's portfolio
- UserNext Generation
- Contributor10 Biotech Stocks on Clinic...
- UserPART 5 JPMorgan 28th Annual...
- Userwishing & hoping
- Usersongjon stock portfolio
- UserAshley 47
- ContributorHealthcare Short Squeezes f...
- Userunkown microcaps
- Userabu1
Latest ISIS Headlines from TheStreet
- Isis Pharmaceuticals CEO Hosts Analyst Day (Transcript) 01.05.12 | 04:01 pm
- ISIS's Development Update Conference 12.15.11 | 05:12 pm
- ISIS CEO Hosts Webcast To Discuss Recent Additions To Its Development Pipeline - Conference Call Transcript 12.15.11 | 05:12 pm
- Stocks Under $10: Value Biotech Stock
11.08.11 | 02:11 pm - Isis Pharmaceuticals CEO Discusses Q3 2011 Results - Earnings Call Transcript 11.07.11 | 09:11 pm
- Isis Stock Hits New 52-Week Low (ISIS) 10.03.11 | 01:10 pm
- ISIS Pharmaceuticals' CEO Discusses Q2 2011 Results - Earnings Call Transcript 08.04.11 | 10:08 pm
- Isis Stock Hits New 52-Week Low (ISIS) 08.04.11 | 04:08 pm
- Stocks Under $10: Biotech Bargain Play 06.22.11 | 09:06 am
- Isis Pharmaceuticals' CEO Discusses Q1 2011 Results - Earnings Call Transcript 05.05.11 | 06:05 pm
Press Releases for ISIS
- Isis Pharmaceuticals To Present At Leerink Swann's 2012 Global Healthcare Conference - PR Newswire 02.08.12 | 07:02 am
- ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions In TTR Protein - PR Newswire 01.05.12 | 08:01 am
- Regulus Therapeutics To Present MicroRNA Platform And Pipeline Updates At Two Leading Scientific Conferences - PR Newswire 01.05.12 | 08:01 am
- Biogen Idec And Isis Pharmaceuticals Announce Global Collaboration For Antisense Program Targeting Spinal Muscular Atrophy - Business Wire 01.04.12 | 08:01 am
- Isis Initiates Phase 1 Clinical Trial Of ISIS-FGFR4Rx A Peripherally Acting Drug To Treat Obesity - PR Newswire 12.20.11 | 08:12 am
- Isis Initiates Phase 1 Clinical Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy - PR Newswire 12.19.11 | 08:12 am
- Isis Updates KYNAMRO Submission Timeline - PR Newswire 12.15.11 | 08:12 am
- Isis Adds Three New Drugs To Its Development Pipeline - PR Newswire 12.14.11 | 07:12 pm
- Isis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding - PR Newswire 12.12.11 | 11:12 am
- Regulus Therapeutics Initiates An Orphan And Rare Disease MicroRNA Therapeutic Effort In Brain Cancer - PR Newswire 12.12.11 | 08:12 am
Partner Headlines for ISIS
- Keeping An Eye On Isis - Seeking Alpha 01.13.12 | 07:01 pm
- The Zacks Analyst Blog Highlights: General Motors, Toyota Motor, Ford Motor, Biogen Idec and Isis Pharmaceuticals - Press Releases - Zacks 01.13.12 | 09:01 am
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- Alnylam States Preclinical Data - Analyst Blog - Zacks 12.30.11 | 04:12 pm
- Pfizer Nets Excaliard Pharma - Analyst Blog - Zacks 12.05.11 | 10:12 am
- Pfizer Signs Another Deal - Analyst Blog - Zacks 11.23.11 | 10:11 am
- Mid-Day Update: Stocks Lower at Session's Half; Revised GDP Data Weighs on Sentiment - NASDAQ 11.22.11 | 05:11 pm
- Wider Loss at Isis Pharma - Analyst Blog - Zacks 11.10.11 | 10:11 am
- Isis Pharmaceuticals 2Q Earnings Down on Rising Costs - Fox Business 08.09.10 | 10:08 am
- UPDATE 1-Isis Pharma Q2 loss wider than expected - Reuters 08.09.10 | 07:08 am
